mesЭкстремальная биомедицинаExtreme Medicine3033-89643033-8972Centre for Strategic Planning of the Federal Medical and Biological Agency10.47183/mes.2022.033mes-138Research ArticleОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕORIGINAL RESEARCHВакцина на основе N-белка SARS-COV-2 формирует выраженный Т-клеточный иммунитет на N-белок новых штаммовN protein based vaccine against SARS-COV-2 produces a strong T cell immune response to N protein of novel strainsРабданоС. О.RabdanoS. O.

Севастьян Олегович Рабдано

ул. Свободы, д. 52, 198320, г. Красное село, г. Санкт-Петербург

Sevastyan O. Rabdano

Svobody, 52, 198320, Krasnoye Selo, Saint Petersburg

sevastyan@rabdano.ruМухинВ. Е.MukhinV. E.

Москва

Moscow

МакаровВ. В.MakarovV. V.

Москва

Moscow

РудаковГ. О.RudakovG. O.

Санкт-Петербург

Saint Petersburg

РузановаЭ. А.RuzanovaE. A.

Санкт-Петербург

Saint Petersburg

АракеловС. А.ArakelovS. A.

Санкт-Петербург

Saint Petersburg

ХаитовМ. Р.KhaitovM. R.

Москва

Moscow

ЮдинС. М.YudinS. M.

Москва

Moscow

КрючкоД. С.KryuchkoD. S.

Москва

Moscow

БерзинИ. А.BerzinI. A.

Москва

Moscow

ЕвтушенкоА. Э.EvtushenkoA. E.

Санкт-Петербург

Saint Petersburg

ТрухинВ. П.TruhinV. P.

Санкт-Петербург

Saint Petersburg

СкворцоваВ. И.SkvortsovaV. I.

Москва

Moscow

Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов Федерального медико-биологического агентстваРоссияSaint Petersburg Scientific Research Institute of Vaccines and Serums and Enterprise for the Production of Bacterial Preparations of the Federal Medical Biological AgencyRussian FederationЦентр стратегического планирования и управления медико-биологическими рисками здоровью Федерального медико-биологического агентстваРоссияCentre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological AgencyRussian FederationИнститут иммунологии Федерального медико-биологического агентства; Российский национальный исследовательский медицинский университет имени Н. И. ПироговаРоссияInstitute of Immunology of the Federal Medical Biological Agency; Pirogov Russian National Research Medical UniversityRussian FederationФедеральное медико-биологическое агентствоРоссияFederal Medical Biological AgencyRussian FederationСанкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов Федерального медико-биологического агентстваРоссияSaint Petersburg Scientific Research Institute of Vaccines and Serums and Enterprise for the Production of Bacterial Preparations of the Federal Medical Biological Agency,Russian Federation202226102024243512Copyright © Рабдано С.О., Мухин В.Е., Макаров В.В., Рудаков Г.О., Рузанова Э.А., Аракелов С.А., Хаитов М.Р., Юдин С.М., Крючко Д.С., Берзин И.А., Евтушенко А.Э., Трухин В.П., Скворцова В.И., 20242024Рабдано С.О., Мухин В.Е., Макаров В.В., Рудаков Г.О., Рузанова Э.А., Аракелов С.А., Хаитов М.Р., Юдин С.М., Крючко Д.С., Берзин И.А., Евтушенко А.Э., Трухин В.П., Скворцова В.И.Rabdano S.O., Mukhin V.E., Makarov V.V., Rudakov G.O., Ruzanova E.A., Arakelov S.A., Khaitov M.R., Yudin S.M., Kryuchko D.S., Berzin I.A., Evtushenko A.E., Truhin V.P., Skvortsova V.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.extrememedicine.ru/jour/article/view/138

Вакцины второго поколения против COVID-19 должны создавать долговременный протективный иммунный ответ по отношению к существующим, а также новым штаммам SARS-CoV-2. Дизайн вакцины Конвасэл® направлен на формирование такого иммунного ответа путем использования N-белка в качестве антигена. Белок N не подвержен быстрому накоплению мутаций и имеет высокую гомологию с нуклеокапсидными белками других β-коронавирусов. Целью работы было провести in vitro исследование возможности Конвасэл® создавать иммунный ответ против штаммов Ухань, Дельта и Омикрон. Мононуклеарные клетки вакцинированных или переболевших добровольцев стимулировали N-белком, а затем методом проточной цитометрии анализировали их специфическую активацию. Результаты показали, что существенный процент CD4+- и CD8+-клеток продуцирует IFNγ и IL2 в ответ на стимуляцию. Статистически значимого снижения ответа для штаммов Дельта и Омикрон по сравнению с штаммом Ухань не выявлено. Полученные результаты поддерживают направление в дизайне вакцин на основе N-белка для создания универсальной вакцины.

The second generation COVID-19 vaccines should produce the long-term protective immune response to the existing and novel strains of SARS-CoV-2. The Convacell® vaccine was designed to produce such immune response by using N protein as an antigen. N-protein is not susceptible to fast accumulation of mutations and is highly homologous to nucleocapsid proteins of other β-coronaviruses. The study was aimed to perform in vitro assessment of the Convacell® vaccine ability to produce immune response to the Wuhan, Delta, and Omicron strains. Mononuclear cells of vaccinated volunteers and survivors were subjected to N protein stimulation. After that specific activation of the cells was assessed by flow cytometry. The results showed that a sibstantial percentage of CD4 and CD8 cells produced IFNγ and IL2 in response to stimulation. No significant reduction of the response to strains Delta and Omicron compared to the Wuhan strain was revealed. The findings support the direction of the N protein based vaccine design towards creation of the universal vaccine.

SARS-CoV-2вакцинаиммунитетновые штаммыN-белокнуклеокапсидДельтаОмикронУханькоронавирусSARS-CoV-2vaccineimmunitynovel strainsN proteinnucleocapsidDeltaOmicronWuhancoronavirusReferencesPark M, Cook AR, Lim JT, Sun Y, Dickens BL. A Systematic Review of COVID-19 Epidemiology Based on Current Evidence. JCM. 2020; 9 (4): 967.Park M, Cook AR, Lim JT, Sun Y, Dickens BL. A Systematic Review of COVID-19 Epidemiology Based on Current Evidence. JCM. 2020; 9 (4): 967.Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, et al. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Review of Anti-infective Therapy. 2021; 19 (7): 877–88.Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, et al. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Review of Anti-infective Therapy. 2021; 19 (7): 877–88.van Oosterhout C, Hall N, Ly H, Tyler KM. COVID-19 evolution during the pandemic – Implications of new SARS-CoV-2 variants on disease control and public health policies. Virulence. 2021; 12 (1): 507–8.van Oosterhout C, Hall N, Ly H, Tyler KM. COVID-19 evolution during the pandemic – Implications of new SARS-CoV-2 variants on disease control and public health policies. Virulence. 2021; 12 (1): 507–8.WHO Coronavirus (COVID-19) Dashboard. [cited 2022 Sep 2]. Available from: https://covid19.who.int/WHO Coronavirus (COVID-19) Dashboard. [cited 2022 Sep 2]. Available from: https://covid19.who.int/Siripanthong B, Asatryan B, Hanff TC, Chatha SR, Khanji MY, Ricci F, et al. The Pathogenesis and Long-Term Consequences of COVID-19 Cardiac Injury. JACC: Basic to Translational Science. 2022; 7 (3): 294–308.Siripanthong B, Asatryan B, Hanff TC, Chatha SR, Khanji MY, Ricci F, et al. The Pathogenesis and Long-Term Consequences of COVID-19 Cardiac Injury. JACC: Basic to Translational Science. 2022; 7 (3): 294–308.Martínez-Salazar B, Holwerda M, Stüdle C, Piragyte I, Mercader N, Engelhardt B, et al. COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences. Front Cell Dev Biol. 2022; 10: 824851.Martínez-Salazar B, Holwerda M, Stüdle C, Piragyte I, Mercader N, Engelhardt B, et al. COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences. Front Cell Dev Biol. 2022; 10: 824851.Liao T, Meng D, Xiong L, Wu S, Yang L, Wang S, et al. Long- Term Effects of COVID-19 on Health Care Workers 1-Year Post- Discharge in Wuhan. Infect Dis Ther. 2022; 11 (1): 145–63.Liao T, Meng D, Xiong L, Wu S, Yang L, Wang S, et al. Long- Term Effects of COVID-19 on Health Care Workers 1-Year Post- Discharge in Wuhan. Infect Dis Ther. 2022; 11 (1): 145–63.Yewdell JW. Antigenic drift: Understanding COVID-19. Immunity. 2021; 54 (12): 2681–7.Yewdell JW. Antigenic drift: Understanding COVID-19. Immunity. 2021; 54 (12): 2681–7.Mittal A, Khattri A, Verma V. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. Stapleford K, editor. PLoS Pathog. 2022; 18 (2): e1010260.Mittal A, Khattri A, Verma V. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. Stapleford K, editor. PLoS Pathog. 2022; 18 (2): e1010260.Heinz FX, Stiasny K. Profiles of current COVID-19 vaccines. Wien Klin Wochenschr. 2021; 133(7–8): 271–83.Heinz FX, Stiasny K. Profiles of current COVID-19 vaccines. Wien Klin Wochenschr. 2021; 133(7–8): 271–83.Garcia-Valtanen P, Hope CM, Masavuli MG, Yeow AEL, Balachandran H, Mekonnen ZA, et al. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents. Cell Reports Medicine. 2022; 3 (6): 100651.Garcia-Valtanen P, Hope CM, Masavuli MG, Yeow AEL, Balachandran H, Mekonnen ZA, et al. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents. Cell Reports Medicine. 2022; 3 (6): 100651.Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. IJMS. 2021; 23 (1): 29.Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. IJMS. 2021; 23 (1): 29.Agerer B, Koblischke M, Gudipati V, Montaño-Gutierrez LF, Smyth M, Popa A, et al. SARS-CoV-2 mutations in MHC-I- restricted epitopes evade CD8 + T cell responses. Sci Immunol. 2021; 6 (57): eabg6461.Agerer B, Koblischke M, Gudipati V, Montaño-Gutierrez LF, Smyth M, Popa A, et al. SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8 + T cell responses. Sci Immunol. 2021; 6 (57): eabg6461.de Silva TI, Liu G, Lindsey BB, Dong D, Moore SC, et al. The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. Science. 2021; 24 (11): 103353.de Silva TI, Liu G, Lindsey BB, Dong D, Moore SC, et al. The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. Science. 2021; 24 (11): 103353.Dolton G, Rius C, Hasan MS, Wall A, Szomolay B, Behiry E, et al. Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope. Cell. 2022; 185 (16): 2936–51.e19.Dolton G, Rius C, Hasan MS, Wall A, Szomolay B, Behiry E, et al. Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope. Cell. 2022; 185 (16): 2936–51.e19.Zhang H, Deng S, Ren L, Zheng P, Hu X, Jin T, et al. Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. Cell Reports. 2021; 36 (11): 109708.Zhang H, Deng S, Ren L, Zheng P, Hu X, Jin T, et al. Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. Cell Reports. 2021; 36 (11): 109708.Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Reports Medicine. 2021; 2 (7): 100355.Tarke A, Sidney J, Methot N, Yu ED, Zhang Y, Dan JM, et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Reports Medicine. 2021; 2 (7): 100355.Jamshidi E, Asgary A, Shafiekhani P, Khajeamiri Y, Mohamed K, Esmaily H, et al. Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines. Human Vaccines & Immunotherapeutics. 2022; 18 (5): 2037384.Jamshidi E, Asgary A, Shafiekhani P, Khajeamiri Y, Mohamed K, Esmaily H, et al. Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines. Human Vaccines & Immunotherapeutics. 2022; 18 (5): 2037384.Dutta NK, Mazumdar K, Gordy JT. The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development. Dutch RE, editor. J Virol. 2020; 94 (13): e00647-20, /jvi/94/13/JVI.00647-20. atom.Dutta NK, Mazumdar K, Gordy JT. The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development. Dutch RE, editor. J Virol. 2020; 94 (13): e00647-20, /jvi/94/13/JVI.00647-20. atom.Thura M, Sng JXE, Ang KH, Li J, Gupta A, Hong JM, et al. Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs. Bioscience Reports. 2021; 41 (9): BSR20211491.Thura M, Sng JXE, Ang KH, Li J, Gupta A, Hong JM, et al. Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs. Bioscience Reports. 2021; 41 (9): BSR20211491.Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS- CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020; 181 (7): 1489–501.e15.Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS- CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020; 181 (7): 1489–501.e15.Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. A Novel Role for Non-Neutralizing Antibodies against Nucleoprotein in Facilitating Resistance to Influenza Virus. J Immunol. 2008; 181 (6): 4168–76.Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. A Novel Role for Non-Neutralizing Antibodies against Nucleoprotein in Facilitating Resistance to Influenza Virus. J Immunol. 2008; 181 (6): 4168–76.Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, et al. Influenza Avirus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice. Virol J. 2012; 9 (1): 322.Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, et al. Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice. Virol J. 2012; 9 (1): 322.LaMere MW, Moquin A, Lee FEH, Misra RS, Blair PJ, Haynes L, et al. Regulation of Antinucleoprotein IgG by Systemic Vaccination and Its Effect on Influenza Virus Clearance. J Virol. 2011; 85 (10): 5027–35.LaMere MW, Moquin A, Lee FEH, Misra RS, Blair PJ, Haynes L, et al. Regulation of Antinucleoprotein IgG by Systemic Vaccination and Its Effect on Influenza Virus Clearance. J Virol. 2011; 85 (10): 5027–35.Vanderven HA, Ana-Sosa-Batiz F, Jegaskanda S, Rockman S, Laurie K, Barr I, et al. What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. EBioMedicine. 2016; 8: 277–90.Vanderven HA, Ana-Sosa-Batiz F, Jegaskanda S, Rockman S, Laurie K, Barr I, et al. What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. EBioMedicine. 2016; 8: 277–90.Wraith DC, Vessey AE, Askonas BA. Purified Influenza Virus Nucleoprotein Protects Mice from Lethal Infection. Journal of General Virology. 1987; 68 (2): 433–40.Wraith DC, Vessey AE, Askonas BA. Purified Influenza Virus Nucleoprotein Protects Mice from Lethal Infection. Journal of General Virology. 1987; 68 (2): 433–40.Gil L, Lopez C, Lazo L, Valdes I, Marcos E, Alonso R, et al. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. International Immunology. 2009; 21 (10): 1175–83.Gil L, Lopez C, Lazo L, Valdes I, Marcos E, Alonso R, et al. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. International Immunology. 2009; 21 (10): 1175–83.Lazo L, Valdes I, Guillén G, Hermida L, Gil L. Aiming at the heart: the capsid protein of dengue virus as a vaccine candidate. Expert Review of Vaccines. 2019; 18 (2): 161–73.Lazo L, Valdes I, Guillén G, Hermida L, Gil L. Aiming at the heart: the capsid protein of dengue virus as a vaccine candidate. Expert Review of Vaccines. 2019; 18 (2): 161–73.Lazo L, Hermida L, Zulueta A, Sánchez J, López C, Silva R, et al. A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine. 2007; 25 (6): 1064–70.Lazo L, Hermida L, Zulueta A, Sánchez J, López C, Silva R, et al. A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine. 2007; 25 (6): 1064–70.Brentville V, Vankemmelbeke M, Metheringham R, Symonds P, Cook K, Urbanowicz R, et al. A novel bivalent DNA vaccine encoding both spike protein receptor-binding domain and nucleocapsid protein of SARS-CoV-2 to elicit T cell and neutralising antibody responses that cross react with variants [Internet]. Immunology. 2021 Jun [cited 2021 Jul 6]. Available from: http://biorxiv.org/lookup/doi/10.1101/2021.06.18.448932Brentville V, Vankemmelbeke M, Metheringham R, Symonds P, Cook K, Urbanowicz R, et al. A novel bivalent DNA vaccine encoding both spike protein receptor-binding domain and nucleocapsid protein of SARS-CoV-2 to elicit T cell and neutralising antibody responses that cross react with variants [Internet]. Immunology. 2021 Jun [cited 2021 Jul 6]. Available from: http://biorxiv.org/lookup/doi/10.1101/2021.06.18.448932Coronavirus3D [Internet]. [cited 2022 Sep 2]. Available from: https://coronavirus3d.org/Coronavirus3D [Internet]. [cited 2022 Sep 2]. Available from: https://coronavirus3d.org/Re3data.Org. GISAID [Internet]. [cited 2022 Sep 2]. Available from: https://www.re3data.org/repository/r3d100010126Re3data.Org. GISAID [Internet]. [cited 2022 Sep 2]. Available from: https://www.re3data.org/repository/r3d100010126Virus Pathogen Database and Analysis Resource (ViPR) - Flaviviridae — VIGOR4 Genome Annotation [Internet]. [cited 2022 Sep 2]. Available from: https://www.viprbrc.org/brc/vigorAnnotator.spg?method=ShowCleanInputPage&decorator=flaviVirus Pathogen Database and Analysis Resource (ViPR) - Flaviviridae — VIGOR4 Genome Annotation [Internet]. [cited 2022 Sep 2]. Available from: https://www.viprbrc.org/brc/ vigorAnnotator.spg?method=ShowCleanInputPage&decorator=flaviUGENE [Internet]. [cited 2022 Sep 2]. Available from: https://ugene.net/UGENE [Internet]. [cited 2022 Sep 2]. Available from: https://ugene.net/MUSCLE [Internet]. [cited 2022 Sep 2]. Available from: https://www.drive5.com/muscleMUSCLE [Internet]. [cited 2022 Sep 2]. Available from: https:// www.drive5.com/muscleTitov A, Shaykhutdinova R, Shcherbakova OV, Serdyuk YV, Sheetikov SA, Zornikova KV, et al. Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2. JCI Insight. 2022; 7 (9): e157699.Titov A, Shaykhutdinova R, Shcherbakova OV, Serdyuk YV, Sheetikov SA, Zornikova KV, et al. Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2. JCI Insight. 2022; 7 (9): e157699.Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021; 374 (6572): abm0829.Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021; 374 (6572): abm0829.Doria-Rose N, Suthar MS, Makowski M, O’Connell S, McDermott AB, Flach B, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021; 384 (23): 2259–61.Doria-Rose N, Suthar MS, Makowski M, O’Connell S, McDermott AB, Flach B, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021; 384 (23): 2259–61.

The authors declare that there are no conflicts of interest present.